TSX:MDNA

Medicenna Therapeutics Corp. Stock Insider Trading

Toronto Stock Exchange > Healthcare > Biotechnology

$2.02

+0.0400 (+2.02%)

At Close: Jun 28, 2024

Medicenna Therapeutics Corp. Stock Insider Power

Based on the 0 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 0 and sold 0 MDNA.TO shares in the last 0 trades.

Historical Insider Trades

There is currently no insider trading information for this ticker.

However, we invite you to learn more about this term and how to use this knowledge to benefit your trading strategy:

Sorry! Image not available at this moment

About Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The... MDNA.TO Profile

Golden Star

Ticker	Date	Change	Price
FFIV	Jun 26	1.75%	$169.26
VIGI	Jun 26	0.694%	$80.72
EHC	Jun 25	1.08%	$84.87
SNAP	Jun 24	6.00%	$15.67
EVBG	Jun 21	0.662%	$34.76
DDOG	Jun 21	10.31%	$117.57
SRE	Jun 20	0.768%	$75.48
PEG	Jun 20	0.163%	$73.58
DOC	Jun 20	1.14%	$19.38
EPD	Jun 18	2.40%	$28.30

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by

Sign In